Biotinylated Human Transferrin R / CD71 Protein, Avitag™,His Tag (MALS verified)
分子别名（Synonym）
CD71,TFRC,TFR,sTfR,TfR1,Trfr,T9,p90
表达区间及表达系统（Source）
Biotinylated Human Transferrin R, Avitag,His Tag (TFR-H82E5) is expressed from human 293 cells (HEK293). It contains AA Cys 89 - Phe 760 (Accession # P02786-1).
Predicted N-terminus: Gly
蛋白结构（Molecular Characterization）
This protein carries an Avi tag (Avitag™) at the N-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 78.7 kDa. The protein migrates as 90-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
The protein is designed as a dimer.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介绍
CD71抗原，亦称转铁蛋白受体1（Transferrin receptor protein 1）、TfR、sTfR、p90、TfR1、Trfr，属于肽酶M28家族及M28B亚家族（注：学界对其酶活性存在争议）。CD71/TFR包含一个PA结构域（蛋白酶相关结构域）。CD71/TfR1是铁从转铁蛋白向细胞内转运的关键介导因子。
CD71作为潜在治疗新靶点，在人类白血病及淋巴瘤中具有重要临床价值。经证实，CD71/TFRC/TfR可与以下分子相互作用：
GABARAP（γ-氨基丁酸A受体相关蛋白）
HFE（遗传性血色素沉着症蛋白）
关键字： Transferrin R;Transferrin R蛋白;Transferrin R重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。